Compounds > 1,2,3,4-tetrahydroisoquinoline
Page last updated: 2024-08-17

1,2,3,4-tetrahydroisoquinoline and leukotriene d4

1,2,3,4-tetrahydroisoquinoline has been researched along with leukotriene d4 in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Berglund, M; Dalence-Guzmán, MF; Jönsson, P; Mesic, A; Persson, CG; Skogvall, S; Sterner, O; Svensson, K1
Bansal, N; Bansal, S; Kumar, M; Rehni, AK; Singh, I; Singh, N1

Other Studies

2 other study(ies) available for 1,2,3,4-tetrahydroisoquinoline and leukotriene d4

ArticleYear
Discovery of a potent and long-acting bronchorelaxing capsazepinoid, RESPIR 4-95.
    Pulmonary pharmacology & therapeutics, 2008, Volume: 21, Issue:1

    Topics: Adrenergic beta-2 Receptor Agonists; Bronchodilator Agents; Calcium Channel Blockers; Capsaicin; Dose-Response Relationship, Drug; Humans; In Vitro Techniques; Leukotriene D4; Lung; Muscle Contraction; Muscle Relaxation; Muscle, Smooth; Tetrahydroisoquinolines

2008
Pharmacological modulation of leukotriene D(4) attenuates the development of opioid dependence in a mouse model of naloxone-induced opioid withdrawal syndrome.
    European journal of pharmacology, 2008, Nov-19, Volume: 598, Issue:1-3

    Topics: Acetates; Animals; Cyclopropanes; Female; Leukotriene Antagonists; Leukotriene D4; Male; Mice; Motor Activity; Naloxone; Narcotic Antagonists; Opioid-Related Disorders; Pain Measurement; Pain Threshold; Quinolines; Signal Transduction; Substance Withdrawal Syndrome; Sulfides; Tetrahydroisoquinolines

2008